• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BriaCell Therapeutics Corp.

    8/1/22 7:00:12 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    SC 13G 1 tm2222010d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ____)*

      

    BriaCell Therapeutics Corp.

    (Name of Issuer)

     

    Common Stock, no par value

    (Title of Class of Securities)

     

    10778Y302

    (CUSIP Number)

     

    July 20, 2022

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     Page 1 of 10 Pages 

     

     

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Lynwood Opportunities Master Fund

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    870,000

    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    OO

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 2 of 10 Pages 

     

     

     

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Lynwood Capital Management Inc.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Ontario, Canada

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER 870,000
    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 3 of 10 Pages 

     

      

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Ben Shapiro

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Canada

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER 870,000
    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    IN

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 4 of 10 Pages 

     

     

    Item 1.

     

    (a)The name of the issuer is BriaCell Therapeutics Corp. (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at Suite 300, 235 15th Street, West Vancouver, British Columbia, V7T 2X1.

     

    Item 2.

     

    (a)This Schedule 13G (this “Statement” or this “Schedule 13G”) is being filed by: (1) Lynwood Opportunities Master Fund, a Cayman Islands entity (the “Fund”); (2) Lynwood Capital Management Inc., an Ontario corporation (the “Investment Manager”); and (3) Ben Shapiro (“Mr. Shapiro”) (all of the foregoing, collectively, the “Reporting Persons”). The Fund is an investment vehicle. The Fund directly beneficially owns the Common Stock (as defined below) reported in this Statement. The Investment Manager is the investment manager of the Fund. Mr. Shapiro is the President, Chief Executive Officer, Chief Investment Officer, sole director and indirect controlling stockholder of the Investment Manager. Mr. Shapiro and the Investment Manager may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the shares directly beneficially owned by such Reporting Person.

     

    (b)

    The principal business office of the Fund is FG Services Limited, Suite 2206, Cassia Court, 72 Market Street, Camana Bay, P.O. Box 30869, Grand Cayman KY1-1204, Cayman Islands. The principal business office of the Investment Manager and Mr. Shapiro is 200 Bay St, Suite 1304, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J1.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)

    This Statement relates to the Common Stock, no par value, of the Issuer (the “Common Stock”).

     

    (e)The CUSIP Number of the Common Stock is 10778Y302.

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________

     

     Page 5 of 10 Pages 

     

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the end of business on July 29, 2022, the business day before the date of filing of this Schedule 13G.

     

    As of the Event Date of July 20, 2022, the Fund owned 796,200 shares of Common Stock, representing 5.1% of the Common Stock outstanding.

     

    The percentages of beneficial ownership contained herein are based on 15.5 million shares of Common Stock outstanding as of June 28, 2022, as reported by the Issuer in an Investor Presentation accessed from the Issuer’s website.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 6 of 10 Pages 

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     Page 7 of 10 Pages 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 1, 2022

     

    Lynwood Opportunities Master Fund

    Lynwood Capital Management Inc.

    Ben Shapiro

     

    By: /s/ Ben Shapiro  
      Ben Shapiro, for himself, and as President, Chief Executive Officer and Chief Investment Officer of the Investment Manager (for itself and on behalf of the Fund)  

     

     

     Page 8 of 10 Pages 

     

     

    EXHIBIT INDEX

     

     

    Exhibit No. Document
       
        1 Joint Filing Agreement

     

     Page 9 of 10 Pages 

    Get the next $BCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

      Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 studyBiomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefitsPositive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patientsPresence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04)Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile PHILADELPHIA and VANCOUVER, British Columbia, Apri

      4/30/25 7:30:59 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

      PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter's option to purchase additional units. Each unit consists of one common share (or pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit was sold to the public at a price of $4.50 per unit (inclusive o

      4/28/25 4:05:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

      Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patientsClinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulationImproved new Bria-OTS+ platform provides powerful innate and adaptive immune system activationPhase 3 biomarker data to be presented on Wed April 30 from 9:00 AM - 12:00 PM CST; Abstract # LB408 PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cance

      4/28/25 7:30:00 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

      2/14/22 6:04:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 4:38:08 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Williams William V.

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 3:22:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Financials

    Live finance-specific insights

    See more
    • ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

      The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

      7/7/23 8:10:00 AM ET
      $BCTX
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

      PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

      2/5/25 6:15:47 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

      PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

      1/3/25 5:05:00 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

      PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

      12/17/24 4:05:59 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    SEC Filings

    See more
    • BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

      4/28/25 4:15:16 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by BriaCell Therapeutics Corp.

      424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)

      4/28/25 9:07:47 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by BriaCell Therapeutics Corp.

      424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)

      4/28/25 9:06:21 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/12/24 6:06:07 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/10/24 6:06:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/5/24 7:45:06 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care